Notch Therapeutics Signals a New Era in CAR-T Therapies

— The T cell therapy company heads to ASH 2024 next month to introduce its novel allogeneic protection and cytokine engineering strategies to support the development of potent and persistent off-the-shelf UNi-T cells —

Notch Therapeutics, Inc., a biotechnology company developing best-in-class T cell therapies for cancer and autoimmune conditions, is excited to announce the acceptance of two abstracts by the American Society of Hematology (ASH) for poster presentations at the 66th American Society of Hematology Annual Meeting and Exposition in San Diego on December 7-10, 2024. The ASH Annual Meeting and Exposition is one of the largest and most respected global gatherings of clinicians and scientists working to conquer blood diseases.

CAR-T therapies have been transforming the treatment of lymphomas, myelomas, and leukemias for years, but the accessibility and reach of these therapies have been limited.

“Notch continues to focus on developing persistent and potent T cell therapies with patient experience and access in mind,” said Chris Bond, Notch’s Chief Scientific Officer. “We’ve built a platform that generates uniformly engineered therapies that may improve on the clinical success of CAR-Ts, while simultaneously tackling the field’s current commercial challenge to supply large quantities of cells made more economically. Our latest preclinical research shows durable and robust tumor control using an engineered cellular product without the need for helper cells or cytokine support, and we are excited to share our findings with hematology experts and the broader oncology community.”

Notch will present two advancements for its allogeneic iPSC-derived CD8 T cell platform. The first is a novel and proprietary strategy to protect Notch’s UNi-T cells from multiple mechanisms of patient immune cell clearance, which aims to enhance cell persistence and durability of patient response. The second focuses on Notch’s proprietary engineered cytokine technology, which eliminates the need for exogenous cytokines or helper cells and creates the potential to administer off-the-shelf T cell therapies without toxic lymphodepleting chemotherapies.

About Notch Therapeutics

Notch Therapeutics is an early-stage biotechnology company developing persistent and potent cell therapies with patient experience and access in mind. Working to make cell therapies more drug-like, cost effective, and accessible, Notch is developing universal T cell products from a renewable cell source: induced pluripotent stem cells (iPSCs). Notch’s UNi-T Cell is an off-the-shelf solution that removes the need for the modification and manufacture of patient-specific cells and signals the dawn of a new era in CAR-T therapies.

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services